{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radium-223+%28Xofigo%2C+BAY88-8223%29", "query": { "intervention": "Radium-223 (Xofigo, BAY88-8223)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radium-223+%28Xofigo%2C+BAY88-8223%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-10T17:37:02.172Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03361735", "title": "Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma" ], "interventions": [ { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Radium Ra 223 Dichloride", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Degarelix", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2018-08-29", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03361735" }, { "nct_id": "NCT03076203", "title": "Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Carcinoma Metastatic to the Bone", "Stage IV Prostate Adenocarcinoma", "Hormone-refractory Prostate Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Radium Ra 223 Dichloride", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 14, "start_date": "2017-09-22", "completion_date": "2022-11-07", "has_results": false, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Chicago, Illinois • New Orleans, Louisiana + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03076203" }, { "nct_id": "NCT02043678", "title": "Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "type": "DRUG" }, { "name": "Matching placebo (normal saline)", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 806, "start_date": "2014-03-30", "completion_date": "2024-02-08", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 29, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043678" }, { "nct_id": "NCT01106352", "title": "A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bone Metastases", "Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 70, "start_date": "2010-07", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 6, "location_summary": "San Francisco, California • Evanston, Illinois • Baltimore, Maryland + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106352" }, { "nct_id": "NCT04489719", "title": "Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Prostate Carcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radium Ra 223 Dichloride", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2021-04-16", "completion_date": "2030-08-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Bozeman, Montana • Seattle, Washington + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Bozeman", "state": "Montana" }, { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04489719" }, { "nct_id": "NCT01934790", "title": "Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 45, "start_date": "2013-12-22", "completion_date": "2017-04-12", "has_results": true, "last_update_posted_date": "2018-03-26", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 3, "location_summary": "New Orleans, Louisiana • Omaha, Nebraska • Syracuse, New York", "locations": [ { "city": "New Orleans", "state": "Louisiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01934790" }, { "nct_id": "NCT03896984", "title": "Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Castration-resistant Prostate Cancer (mCRPC)" ], "interventions": [ { "name": "Radium-223 (Xofigo, BAY88-8223)", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 346, "start_date": "2019-03-18", "completion_date": "2020-12-14", "has_results": false, "last_update_posted_date": "2021-12-29", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 1, "location_summary": "Whippany, New Jersey", "locations": [ { "city": "Whippany", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896984" }, { "nct_id": "NCT03317392", "title": "Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radium Ra 223 Dichloride", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 132, "start_date": "2019-02-04", "completion_date": "2027-02-16", "has_results": true, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 22, "location_summary": "La Jolla, California • Sacramento, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03317392" }, { "nct_id": "NCT03344211", "title": "Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Radium Ra 223 Dichloride", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2018-11-21", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03344211" }, { "nct_id": "NCT02605356", "title": "Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-10", "completion_date": "2021-07", "has_results": false, "last_update_posted_date": "2016-10-07", "last_synced_at": "2026-10-10T17:37:02.172Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Encinitas, California + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605356" } ] }